Skip to main content
Clinical Trials/EUCTR2013-000276-15-BE
EUCTR2013-000276-15-BE
Active, not recruiting
Phase 1

Feasibility study of the (intravenously injected) Indocyanine green (ICG) imaging of tumoral implants in patients with peritoneal carcinomatosis from ovarian carcinoma

Jules Bordet Institute0 sitesFebruary 15, 2013

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Jules Bordet Institute
Status
Active, not recruiting
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 15, 2013
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Patients (either newly diagnosed, or relapsing) with histo\-pathological diagnosis of ovarian carcinoma and peritoneal carcinomatosis who are candidate for open” surgery, either after neo\-adjuvant chemotherapy (80\-90% of the cases), or in first intent”.
  • \- Informed consent form signed.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 10
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • \- Age less than18 years old.
  • \- Inability to give informed consent.
  • \- History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.
  • \- Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or dissemi\-nated autonomies of the thyroid gland.
  • \- Documented coronary disease.
  • \- Advanced renal impairment (creatinine \> 1,5mg/dl).

Outcomes

Primary Outcomes

Not specified

Similar Trials